Rare disease advocacy group taps Prometheus to build data assets
Prometheus Research enters into an agreement with the Primary Ciliary Dyskinesia Foundation to advance research through its clinical data platform.
Prometheus Research enters into an agreement with the Primary Ciliary Dyskinesia Foundation to advance research through its clinical data platform.
Eye-on-a-chip with blinking eyelid shows potential as a drug screening platform for ocular conditions such as dry-eye disease.
Genecentric’s immuno-oncology drug development solutions are bolstered through acquisition of Select Immunogenomics’ biomarker development services.
GSK announces that its injectable HIV treatment was able to suppress the virus when administered every two months.
FDA approves Nabriva’s Xenleta to add to the available treatments for bacterial pneumonia, with the aim of fighting antimicrobial resistance.